Background Hyperglycaemia associated with myocardial oxidative stress and fibrosis is the
main cause of diabetic cardiomyopathy. Empagliflozin, a sodium-glucose cotransporter 2 …

Cardiovascular complications contribute to the major mortality and morbidity in type 2
diabetes. Diabetic cardiomyopathy (DCM) is increasingly recognized as an important cause …

Hyperglycemia associated with inflammation and oxidative stress is a major cause of
vascular dysfunction and cardiovascular disease in diabetes. Recent data reports that a …

Background The potential benefit of SGLT2 inhibitors in metabolic syndrome is with
prediabetic stage unclear. This work was undertaken to investigate the non-glycemic effect …

Glucagon-like peptide 1 receptor agonists (GLP-1RAs) and sodium-glucose cotransporter-2
inhibitors (SGLT2is) are antihyperglycemic agents with cardioprotective properties against …

Diabetic cardiomyopathy (DCM) is considered to be a critical contributor to the development
of heart failure. Empagliflozin (EMPA), a sodium‐glucose cotransporter 2 inhibitor, has been …

Objectives Sodium-glucose cotransporter 2 (SGLT2) inhibitors have been confirmed to
reduce the rate of rehospitalization for heart failure and cardiovascular death in diabetic …

Background Empagliflozin (EMPA), a selective inhibitor of the sodium glucose co-transporter
2, reduced the risk of hospitalization for heart failure and cardiovascular death in type 2 …

Abstract Background/Aims: This study aimed to determine whether or not the sodium-
glucose co-transporter 2 inhibitor, empagliflozin (EMPA), can protect against diabetic …

Background Sodium glucose co-transporter 2 inhibitor (SGLT2i), a new class of anti-diabetic
drugs acting on inhibiting glucose resorption by kidneys, is shown beneficial in reduction of …